Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
ACR/ARHP Annual Meeting 2015
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.